Zusammenfassung
Therapieresistenz wird nach wie vor in vielen unterschiedlichen Varianten definiert. Ein fehlender offizieller Konsens über die Definition einer Vielzahl von Details im Zusammenhang mit der Beschreibung der betroffenen Patientengruppe erschwert die Durchführung von aussagekräftigen Studien zur Therapieresistenz wie auch die Interpretation der vorliegenden wissenschaftlichen Befunde. Ziel einer erfolgreichen Akuttherapie sollte die Remission und nicht die Response sein, in der Langzeittherapie dementsprechend die dauerhaft anhaltende Remission. Der Begriff »therapieresistent« sollte dem Begriff »therapierefraktär« vorgezogen werden, letzterer impliziert zu Unrecht das fehlende Ansprechen auf jegliche denkbare Therapiestrategie.
Forschungsschwerpunkte auf dem Gebiet der Therapieresistenz befassen sich mit Fragen der Kodierung und Stadieneinteilung, der Weiterentwicklung von geeigneten Skalen zur Dokumentation der Therapieresistenz und der Definition von geeigneten Outcomekriterien. Weiterhin müssen Definitionen erarbeitet werden, welche Therapieversuche als adäquat hinsichtlich Dauer und Dosis zu werten sind und welche Bedeutung die retrospektive und die prospektive Erhebung von Kriterien der Therapieresistenz des Patienten haben. Methodische Gesichtspunkte beim Entwurf passender Studiendesigns betreffen vor allem die Wahrung wissenschaftlicher Präzision einerseits und die Möglichkeit der Übertragung der Studienergebnisse in die klinische Praxis andererseits.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Altshuler LL, Cohen LS, Moline ML, Kahn DA, Carpenter D, Docherty JP (2001) Expert Consensus Panel for Depression in Women: The expert consensus guideline series. Treatment of depression in women. Postgrad Med 111 (Special Issue): 1–107
American Academy of Child and Adolescent Psychiatry (1998) Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 37[Suppl 10]: 63S–83S
American Psychiatric Assocation (1993) Practice guideline for major depressive disorder in adults. Am J Psychiatry 150[Suppl 4]: 1–26
American Psychiatric Association (2000) Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157[Suppl 4]: 1–45
Anderson IM, Nutt DJ, Deakin JFW (2000) Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 14: 3–20
Ballenger JC (1999) Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 60[Suppl 22]: 29–34
Barbee JG, Jamhour NJ (2002) Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry 63: 737–741
Bauer M, Adli M, Kiesslinger U, Neu P, Smolka M, Linden M (2001) Algorithm-guided treatment versus treatment as usual: randomized trial in inpatients with depression [abstract]. 154th Annual Meeting, American Psychiatric Association, May 5–10, 2001, New Orleans, USA
Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ (2002a) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatr 3: 5–43
Bauer M, Whybrow PC, Angst J, Versiani M, Moller H-J, WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2002b) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 3: 69–86
Burt T, Lisanby SH, Sackeim HA (2002) Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. Int J Neuropsychopharmacol 5: 73–103
Canadian Psychiatric Association (2001) Clinical Guidelines for the Treatment of Depressive Disorders. Can J Psychiatry 46[Suppl 1]: 5S–90S
Crismon ML, Trivedi M, Pigott TA et al. (1999) The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry 60: 142–156
Crown WH, Finkelstein S, Berndt ER et al. (2002) The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 63: 963–971
Depression Guideline Panel (1993) Clinical practice guideline, number 5. Depression in primary care, vol 2: Treatment of major depression. U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, Rockville/MD. AHCPR Publication 93-0551
Ezquiaga E, Garcia A, Pallares T, Bravo MF (1999) Psychosocial predictors of outcome in major depression: a prospective 12-month study. J Affect Disord 52: 209–216
Fava M (2003) Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53: 649–659
Fava GA, Fabbri S, Sonino N (2002) Residual symptoms in depression: an emerging therapeutic target. Prog Neuropsychopharmacol Biol Psychiatry 26: 1019–1027
Fava M, Rush AJ, Trivedi MH et al. (2003) Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 26: 457–494
Greden JF (ed) (2001) Clinical prevention of recurrent depression. The need for paradigm shifts in treatment of recurrent depression. American Psychiatric Press, Washington DC
Hirschfeld RM, Keller MB, Panico S et al. (1997) The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 277: 333–340
Hirschfeld RM, Dunner DL, Keitner G et al. (2002) Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry 51: 123–133
Iosifescu DV, Nierenberg AA, Alpert JE, Smith M, Bitran S, Dording C, Fava M (2003) The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry 160: 2122–2127
Judd LL, Akiskal HS, Maser JD et al. (1998a) A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 55: 694–700
Judd LL, Akiskal HS, Maser JD et al. (1998b) Major depressive disorder: A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 50: 97–108
Kanai T, Takeuchi H, Furukawa TA, Yoshimura R, Imaizumi T, Kitamura T, Takahashi K (2003) Time to recurrence after recovery from major depressive episodes and its predictors. Psychol Med 33: 839–845
Keitner GI, Ryan CE, Miller IW, Kohn R, Epstein NB (1991) 12-month outcome of patients with major depression and comorbid psychiatric or medical illness (compound depression). Am J Psychiatry 148: 345–350
Keitner GI, Ryan CE, Miller IW, Norman WH (1992) Recovery and major depression: factors associated with twelvemonth outcome. Am J Psychiatry 149: 93–99
Keller MB, McCullough JP, Klein DN et al. (2000) A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 342: 1462–1470
Kessler RC, Berglund P, Demler O et al. (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289: 3095–3105
Khan A, Dager SR, Cohen S, Avery DH, Scherzo B, Dunner DL (1991) Chronicity of depressive episode in relation to antidepressant—placebo response. Neuropsychopharmacol 4: 125–130
Koran LM, Gelenberg AJ, Kornstein SG et al. (2001) Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord 65: 27–36
Lizardi H, Klein DN, Ouimette PC, Riso LP, Anderson RL, Donaldson SK (1995) Reports of the childhood home environment in early-onset dysthymia and episodic major depression. J Abnorm Psychol 104: 132–139
McCullough JP Jr (2001) Skills training manual for diagnosing and treating chronic depression: cognitive behavioral analysis system of psychotherapy. Guilford, New York
Miller IW, Keitner GI, Schatzberg AJ et al. (1998) The treatment of chronic depression. Part 3: Psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 59: 608–619
Nemeroff CB, Heim CM, Thase ME et al. (2003) Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA 100: 14.293–14.296
Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J (1994) Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 14: 419–423
Oquendo MA, Malone KM, Ellis SP, Sackeim HA, Mann JJ (1999) Antidepressant treatment is inadequate in patients with major depression who are at risk for suicidal behavior. Am J Psychiatry 156: 190–194
Paykel ES, Hollyman JA, Freeling P, Sedgwick P (1988) Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. J Affect Disord 14: 83–95
Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barokka A (1995) Residual symptoms after partial remission: an important outcome in depression. Psychol Med 25: 1171–1180
Paykel ES, Scott J, Teasdale JD et al. (1999) Prevention of relapse in residual depression by cognitive therapy. A controlled trial. Arch Gen Psychiatry 56: 829–835
Prien RF, Kupfer DJ (1986) Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry 143: 18–23
Prudic J, Sackeim HA, Devanand DP (1990) Medication resistance and clinical response to electroconvulsive therapy. Psychiatry Res 31: 287–296
Prudic J, Haskett RF, Mulsant B et al. (1996) Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry 153: 985–992
Quitkin FM, Stewart JW, McGrath PJ et al. (1988) Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 145: 306–311
Quitkin FM, Stewart JW, McGrath PJ et al. (1993) Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry 21[Suppl]: 30–34
Quitkin FM, Petkova E, McGrath PJ et al. (2003) When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry 160: 734–740
Reesal RT, Lam RW (2001) CANMAT Depression Work Group: Clinical guidelines for the treatment of depressive disorders. II. Principles of management. Can J Psychiatry 46[Suppl 1]: 21S–28S
Riso LP, Thase ME, Howland RH, Friedman ES, Simons AD, Tu XM (1997) A prospective test of criteria for response, remission, relapse, recovery, and recurrence in patients treated with cognitive behavior therapy. J Affect Disord 43: 131–142
Rush AJ, Ryan ND (2002) Current and emerging therapeutics for depression. In: Davis KL, Charney D, Coyle JT, Nemeroff C (eds) Neuropsychopharmacology. The Fifth Generation of Progress. Lippincott Williams & Wilkins, Philadelphia, pp 1081–1095
Rush AJ, Thase ME (1997) Strategies and tactics in the treatment of chronic depression. J Clin Psychiatry 58[Suppl 13]: 14–22
Rush AJ, George MS, Sackeim HA et al. (2000) Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry 47: 276–286
Rush AJ, Trivedi MH, Carmody TJ et al. (2001) Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacol 25: 131–138
Rush AJ, Crismon ML, Kashner TM et al. (2003a) Texas Medication Algorithm Project, Phase 3 (TMAP-3): rationale and study design. J Clin Psychiatry 64: 357–369
Rush AJ, Thase ME, Dubé S (2003b) Research issues in the study of difficult to treat depression. Biol Psychiatry 53: 743–753
Rush AJ, Fava M, Wisniewski SR et al. for the STAR*D Investigators Group (2004) Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design. Control Clin Trials 25: 119–142
Russell JM, Hawkins K, Ozminkowski RJ et al. (2004) The cost consequences of treatment-resistant depression. J Clin Psychiatry 65: 341–347
Sackeim HA (2001) The definition and meaning of treatmentresistant depression. J Clin Psychiatry 62[Suppl 16]: 10–17
Sackeim HA, Prudic J, Devanand DP et al. (1990) The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol 10: 96–104
Sackeim HA, Prudic J, Devanand DP et al. (2000) A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry 57: 425–434
Sackeim HA, Rush AJ, George MS et al. (2001) Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacol 25: 713–728
Schlaepfer JE, Kosel M (2004) Transcranial magnetic stimulation in depression. In: Lisanby S (ed) Brain stimulation in psychiatric treatment. American Psychiatric Publishing, Washington DC
Schatzberg AF, Rush AJ, Arnow BA et al. (submitted) Medication or psychotherapy is effective when the other is not in chronic depression: Empirical support
Shelton RC, Tollefson GD, Tohen M et al. (2001) A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 158: 131–134
Simon GE, Manning WG, Katzelnick DJ, Pearson SD, Henk HJ, Helstad CS (2001) Cost-effectiveness of systematic depression treatment for high utilizers of general medical care. Arch Gen Psychiatry 58: 181–187
Tedlow J, Fava M, Uebelacker L, Nierenberg AA, Alpert JE, Rosenbaum J (1998) Outcome definitions and predictors in depression. Psychother Psychosom 67: 266–270
Thase ME, Rush AJ (1995) Treatment-resistant depression. In: Bloom F, Kupfer DJ (eds) Psychopharmacology: The fourth generation of progress. Raven, New York, pp 1081–1097
Thase ME, Rush AJ (1997) When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 58[Suppl 13]: 23–29
Thase ME, Frank E, Mallinger AG, Hamer T, Kupfer DJ (1992) Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 53: 5–11
Trivedi MH, DeBattista C, Fawcett J, Nelson C, Osser DN, Stein D, Jobson K (1998) Developing treatment algorithms for unipolar depression in cyberspace: International Psychopharmacology Algorithm Project (IPAP). Psychopharmacol Bull 34: 355–359
Trivedi MH, Rush AJ, Pan JY, Carmody TJ (2001) Which depressed patients respond to nefazodone and when? J Clin Psychiatry 62: 158–163
Viinamaki H, Hintikka J, Tanskanen A et al. (2002) Partial remission in major depression: a two-phase; 12-month prospective study. Nord J Psychiatry 56: 33–37
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Rush, A. (2005). Aktueller Stand und Perspektiven der Forschung. In: Bauer, M., Berghöfer, A., Adli, M. (eds) Akute und therapieresistente Depressionen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-28049-9_1
Download citation
DOI: https://doi.org/10.1007/3-540-28049-9_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-40617-4
Online ISBN: 978-3-540-28049-1
eBook Packages: Medicine (German Language)